Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3757749
- 228 Pages
- January 2020
- Healthcare
Psoriatic arthritis is an autoimmune disease caused by an attack of body’s immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.
Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.
The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
• NSAIDs
• DMARDs
• Biologics
• Others
By Type
• Prescription
• OTC
By Route of Administration
• Topical
• Oral
• Injectable
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly And Company
• Johnson & Johnson
• Merck & Co Inc.
• Novartis AG
• Pfizer Inc.
• UCB S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• F. Hoffmann-La Roche AG
• Valeant Pharmaceuticals International, Inc.
• Abbott Laboratories
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of psoriasis & psoriatic arthritis disease
3.4.1.2. Increase in number of pipeline drugs
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. NSAIDs
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. DMARDs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Biologics
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. OTC
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Injectable
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Oral
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Topical
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. psoriatic arthritis treatment market, by drug type
7.2.2.1.2. U.S. psoriatic arthritis treatment market, by type
7.2.2.1.3. U.S. psoriatic arthritis treatment market, by route of administration
7.2.2.2. Canada
7.2.2.2.1. Canada psoriatic arthritis treatment market, by drug type
7.2.2.2.2. Canada psoriatic arthritis treatment market, by type
7.2.2.2.3. Canada psoriatic arthritis treatment market, by route of administration
7.2.2.3. Mexico
7.2.2.3.1. Mexico psoriatic arthritis treatment market, by drug type
7.2.2.3.2. Mexico psoriatic arthritis treatment market, by type
7.2.2.3.3. Mexico psoriatic arthritis treatment market, by route of administration
7.2.3. North America market size and forecast, by drug type
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by route of administration
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany psoriatic arthritis treatment market, by drug type
7.3.2.1.2. Germany psoriatic arthritis treatment market, by type
7.3.2.1.3. Germany psoriatic arthritis treatment market, by route of administration7.3.2.2. France
7.3.2.2.1. France psoriatic arthritis treatment market, by drug type
7.3.2.2.2. France psoriatic arthritis treatment market, by type
7.3.2.2.3. France psoriatic arthritis treatment market, by route of administration
7.3.2.3. UK
7.3.2.3.1. UK psoriatic arthritis treatment market, by drug type
7.3.2.3.2. UK psoriatic arthritis treatment market, by type
7.3.2.3.3. UK psoriatic arthritis treatment market, by route of administration
7.3.2.4. Italy
7.3.2.4.1. Italy psoriatic arthritis treatment market, by drug type
7.3.2.4.2. Italy psoriatic arthritis treatment market, by type
7.3.2.4.3. Italy psoriatic arthritis treatment market, by route of administration
7.3.2.5. Spain
7.3.2.5.1. Spain psoriatic arthritis treatment market, by drug type
7.3.2.5.2. Spain psoriatic arthritis treatment market, by type
7.3.2.5.3. Spain psoriatic arthritis treatment market, by route of administration
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe psoriatic arthritis treatment market, by drug type
7.3.2.6.2. Rest of Europe psoriatic arthritis treatment market, by type
7.3.2.6.3. Rest of Europe psoriatic arthritis treatment market, by route of administration
7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe market size and forecast, by type
7.3.5. Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan psoriatic arthritis treatment market, by drug type
7.4.2.1.2. Japan psoriatic arthritis treatment market, by type
7.4.2.1.3. Japan psoriatic arthritis treatment market, by route of administration
7.4.2.2. China
7.4.2.2.1. China psoriatic arthritis treatment market, by drug type
7.4.2.2.2. China psoriatic arthritis treatment market, by type
7.4.2.2.3. China psoriatic arthritis treatment market, by route of administration
7.4.2.3. Australia
7.4.2.3.1. Australia psoriatic arthritis treatment market, by drug type
7.4.2.3.2. Australia psoriatic arthritis treatment market, by type
7.4.2.3.3. Australia psoriatic arthritis treatment market, by route of administration
7.4.2.4. India
7.4.2.4.1. India psoriatic arthritis treatment market, by drug type
7.4.2.4.2. India psoriatic arthritis treatment market, by type
7.4.2.4.3. India psoriatic arthritis treatment market, by route of administration
7.4.2.5. South Korea
7.4.2.5.1. South Korea psoriatic arthritis treatment market, by drug type
7.4.2.5.2. South Korea psoriatic arthritis treatment market, by type
7.4.2.5.3. South Korea psoriatic arthritis treatment market, by route of administration
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific psoriatic arthritis treatment market, by drug type
7.4.2.6.2. Rest of Asia-Pacific psoriatic arthritis treatment market, by type
7.4.2.6.3. Rest of Asia-Pacific psoriatic arthritis treatment market, by route of administration
7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific market size and forecast, by type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil psoriatic arthritis treatment market, by drug type
7.5.2.1.2. Brazil psoriatic arthritis treatment market, by type
7.5.2.1.3. Brazil psoriatic arthritis treatment market, by route of administration
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia psoriatic arthritis treatment market, by drug type
7.5.2.2.2. Saudi Arabia psoriatic arthritis treatment market, by type
7.5.2.2.3. Saudi Arabia psoriatic arthritis treatment market, by route of administration
7.5.2.3. South Africa
7.5.2.3.1. South Africa psoriatic arthritis treatment market, by drug type
7.5.2.3.2. South Africa psoriatic arthritis treatment market, by type
7.5.2.3.3. South Africa psoriatic arthritis treatment market, by route of administration
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA psoriatic arthritis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA psoriatic arthritis treatment market, by type
7.5.2.4.3. Rest of LAMEA psoriatic arthritis treatment market, by route of administration
7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA market size and forecast, by type
7.5.5. LAMEA market size and forecast, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Amgen Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Bristol-Myers Squibb Company
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Eli Lilly And Company.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Johnson & Johnson.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Merck & Co Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Mylan N.V
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Pfizer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. UCB S.A.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
TABLE 01. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. NSAIDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. DMARDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. BIOLOGICS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. PRESCRIPTION PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTC PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 10. INJECTABLE PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. ORAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. TOPICAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 13. PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 15. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 16. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 17. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 18. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 20. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 21. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 23. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 24. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 25. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 26. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 27. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 28. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 29. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 30. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 31. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 33. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 34. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 35. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 36. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 37. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 38. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 39. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 40. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 42. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 43. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 44. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 45. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 46. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 48. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 49. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 51. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 52. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 53. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 55. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 56. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 57. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 58. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 59. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 61. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 62. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 63. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 64. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 65. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 66. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 68. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 69. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 70. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 71. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 72. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 73. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 74. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 75. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 76. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 77. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 78. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 79. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 80. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 81. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 82. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 83. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 84. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 85. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 86. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 87. ABBVIE INC: COMPANY SNAPSHOT
TABLE 88. ABBVIE INC: OPERATING SEGMENTS
TABLE 89. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 90. AMGEN: COMPANY SNAPSHOT
TABLE 91. AMGEN: PRODUCT SEGMENT
TABLE 92. AMGEN: PRODUCT PORTFOLIO
TABLE 93. BMS.: OPERATING SEGMENT
TABLE 94. BMS.: PRODUCT PORTFOLIO
TABLE 95. LILLY: COMPANY SNAPSHOT
TABLE 96. LILLY: OPERATING SEGMENTS
TABLE 97. LILLY: PRODUCT PORTFOLIO
TABLE 98. J&J: COMPANY SNAPSHOT
TABLE 99. J&J: OPERATING SEGMENTS
TABLE 100. J&J: PRODUCT PORTFOLIO
TABLE 101. MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 102. MERCK & CO., INC: OPERATING SEGMENTS
TABLE 103. MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 104. MYLAN: COMPANY SNAPSHOT
TABLE 105. MYLAN: OPERATING SEGMENTS
TABLE 106. MYLAN: PRODUCT PORTFOLIO
TABLE 107. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 108. NOVARTIS AG: OPERATING SEGMENTS
TABLE 109. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 110. PFIZER INC: COMPANY SNAPSHOT
TABLE 111. PFIZER INC: OPERATING SEGMENTS
TABLE 112. PFIZER INC: PRODUCT PORTFOLIO
TABLE 113. UCB S.A.: COMPANY SNAPSHOT
TABLE 114. UCB S.A.: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
